Citadel Advisors’s Tyra Biosciences TYRA Stock Holding History

Citadel Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$559K	Buy	14,600 +2,100	+17%	+$68K	﹤0.01%	9035
2025 Q4	$329K	Sell	12,500 -11,000	-47%	-$202K	﹤0.01%	9946
2025 Q3	$329K	Buy	+23,500	New	+$268K	﹤0.01%	10147
2025 Q2	–	Sell	-14,200	Closed	-$132K	–	15177
2025 Q1	$132K	Buy	14,200 +10,400	+274%	+$135K	﹤0.01%	11064
2024 Q4	$52.8K	Sell	3,800 -17,800	-82%	-$323K	﹤0.01%	12338
2024 Q3	$508K	Buy	+21,600	New	+$453K	﹤0.01%	8230
2024 Q2	–	Sell	-600	Closed	-$9.84K	–	15441
2024 Q1	$9.84K	Buy	+600	New	+$9.84K	﹤0.01%	13480
2023 Q1	–	Sell	-4,100	Closed	-$31.2K	–	15535
2022 Q4	$31.2K	Buy	+4,100	New	+$29K	﹤0.01%	12700

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Citadel Advisors's TYRA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Tyra Biosciences (TYRA) in Q1 2026: 15,396 shares worth $590K. The stake represents ﹤0.01% of the portfolio and ranks #8899 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TYRA as recently as Q3 2025.

Citadel Advisors first reported a position in TYRA in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.07M in Q2 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

Citadel Advisors held 15,396 shares of Tyra Biosciences worth $590K as of Q1 2026.
Tyra Biosciences was a new Citadel Advisors position in Q1 2026.
Tyra Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8899 holding.
Citadel Advisors first reported a position in Tyra Biosciences in Q4 2021 and has held it in 12 quarters since.
Citadel Advisors's Tyra Biosciences position peaked at $2.07M in Q2 2025.
164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.